Kabra Drugs Ltd. (BSE: 524322) is a Chennai, Tamil Nadu-based company in the Pharmaceuticals industry. With a market capitalisation of ₹49 Cr, it ranks #3,811 by market cap among the 6,197 Indian listed companies on FinBizNet, and #51 of 63 in Pharmaceuticals. At ₹20.50 (as of 16 Nov 2026), the share price is 42.3% below its 52-week high of ₹35.52 and 34.4% above its 52-week low of ₹15.25. The share price is up 6.6% over one year and down 14.6% over three months.
| Current Price | ₹20.50 |
|---|---|
| Market Cap | ₹49 Cr |
| BSE Code | 524322 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 9.9 |
| Return on Equity | 18.28% |
| Return on Assets | 5.89% |
| 52-Week Range | ₹15.25 – ₹35.52 |
| 1-Year Price Change | +6.6% |
| 3-Month Price Change | -14.6% |
| Beta (1Y) | 0.48 |
| Headquarters | Chennai, Tamil Nadu |
| Website | www.kabradrugs.com |
| Revenue | ₹46 Cr |
|---|---|
| Net Profit | ₹2 Cr |
| Net Margin | 4.6% |
| EPS (Basic) | ₹0.90 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Kabra Drugs Ltd. reported revenue of ₹46 Cr in Q1 FY27, up 546.4% from ₹7 Cr in Q1 FY26 and up 30.5% from ₹35 Cr in Q4 FY26. It posted a net profit of ₹2 Cr for the quarter, against a net loss of ₹1 Cr in Q1 FY26. Across the 8 quarters from Q2 FY25 to Q1 FY27, quarterly revenue ranged from ₹0 Cr (Q4 FY25) to ₹46 Cr (Q1 FY27). The company reported a net loss in 3 of these 8 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q1 FY27 | ₹46 Cr | ₹2 Cr | 4.6% |
| Q4 FY26 | ₹35 Cr | ₹1 Cr | 3.0% |
| Q3 FY26 | ₹30 Cr | ₹3 Cr | 8.4% |
| Q2 FY26 | ₹20 Cr | ₹2 Cr | 9.3% |
| Q1 FY26 | ₹7 Cr | −₹1 Cr | −7.0% |
| Q4 FY25 | ₹0 Cr | ₹0 Cr | — |
| Q3 FY25 | ₹0 Cr | −₹1 Cr | — |
| Q2 FY25 | ₹0 Cr | −₹0 Cr | — |
Standalone figures (₹ crore, XBRL filings).
Promoters held 60.49% of Kabra Drugs Ltd.'s shares as of Mar 2026, against 60.24% in Mar 2025 (+0.25 percentage points). Delivery averaged 75.8% of traded volume across 15 BSE sessions (21 Oct 2026 – 13 Nov 2026).
Kabra Drugs Limited does not have significant operations. Previously, the company was engaged in permaculture manufacturing and trading of pharma related products. Kabra Drugs Limited was incorporated in 1989 and is based in Chennai, India.
1. Pharmaceuticals-This segment engages in the manufacture and sale of drugs in India. It offers ether, derivative, and pharmaceutical formulations. It manufactures ether derivatives, which include diethyl and solvent ethers, ethyl chloride sprays, and surgical products; liquid and dry injections, softgelatine capsules, and ethical based products; and a range of disinfectants, such as hand wash, hand sanitizer, and antimicrobial gels.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Kabra Drugs Ltd. | ₹49 Cr | 9.9 | 18.28% | ₹46 Cr | +6.6% |
Listed by market capitalisation. Ratios are shown for context only.
Kabra Drugs Ltd. is trading at ₹20.50, with a market capitalisation of ₹49 Cr.
Kabra Drugs Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Kabra Drugs Ltd. has a P/E of 9.9 and a return on equity of 18.28%.
Kabra Drugs Ltd. is listed on the BSE under the scrip code 524322.
Kabra Drugs Ltd.'s share price is up 6.6% over one year and down 14.6% over three months. Its 52-week range is ₹15.25 to ₹35.52.
In Q1 FY27, Kabra Drugs Ltd. reported revenue of ₹46 Cr and net profit of ₹2 Cr, with basic EPS of ₹0.9 (standalone, parsed from the company's exchange filing).
Kabra Drugs Ltd. reported revenue of ₹46 Cr in Q1 FY27, up 546.4% from ₹7 Cr in Q1 FY26 and up 30.5% from ₹35 Cr in Q4 FY26.
Promoters held 60.49% of Kabra Drugs Ltd.'s shares as of Mar 2026, against 60.24% in Mar 2025 (+0.25 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.